Should we screen for bladder cancer in a high‐risk population?

The U.S. Food and Drug Administration recently approved screening high‐risk patients for bladder cancer using urine‐based markers. The cost and life‐years saved associated with bladder cancer screening were evaluated.

[1]  Giovanni Parmigiani,et al.  A Model-Based Comparison of Breast Cancer Screening Strategies: Mammograms and Clinical Breast Examinations , 2005, Cancer Epidemiology Biomarkers & Prevention.

[2]  A. Dowell,et al.  A community study of bladder cancer screening by the detection of occult urinary bleeding. , 1992, The Journal of urology.

[3]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[4]  W. Fair,et al.  Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Messing,et al.  Detection of bladder cancer using a point-of-care proteomic assay. , 2005, JAMA.

[6]  M. Gold,et al.  Standardizing cost-effectiveness analyses: the panel on cost-effectiveness in health and medicine. , 1998, Academic Radiology.

[7]  P. Humphrey,et al.  Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors , 2002, Cancer.

[8]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Agarwal,et al.  Screening and monitoring for bladder cancer: refining the use of NMP22. , 2001, The Journal of urology.

[10]  H. Grönberg,et al.  A quantitative analysis of the costs and benefits of prostate cancer screening , 2001, Prostate Cancer and Prostatic Diseases.

[11]  E. Messing,et al.  Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. , 1995, Urology.

[12]  C. J. Rosenquist,et al.  Screening mammography beginning at age 40 years , 1998, Cancer.

[13]  Alberto Redaelli,et al.  The health economics of bladder cancer: a comprehensive review of the published literature. , 2003, PharmacoEconomics.

[14]  Yair Lotan,et al.  Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy , 2005 .

[15]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[16]  A. Agarwal,et al.  NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. , 1999, Anticancer research.

[17]  R. Sylvester,et al.  Factors affecting recurrence and progression in superficial bladder tumours. , 1995, European journal of cancer.

[18]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[19]  L. Kiemeney,et al.  The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. , 1993, British Journal of Cancer.

[20]  J. Palou,et al.  Multivariate analysis of the prognostic factors of primary superficial bladder cancer. , 2000, The Journal of urology.

[21]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[22]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Kiemeney,et al.  Epidemiology of Bladder Cancer , 1999, European Urology.

[24]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[25]  Michael Pignone,et al.  Screening for Colorectal Cancer in Adults at Average Risk: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[26]  Y. Lotan,et al.  Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. , 2006, Urologic oncology.

[27]  H. Maartmann-Moe,et al.  The long‐term outcome in patients with superficial transitional cell carcinoma of the bladder: a single‐institutional experience , 1999, BJU international.

[28]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[29]  Y. Lotan,et al.  Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Messing,et al.  Hematuria screening for bladder cancer. , 1990, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[31]  J. McKiernan,et al.  Controversies in prostate cancer screening. , 2004, The Journal of urology.